Rare but life-threatening aspiration pneumonia related to initiation of clobazam therapy
Clobazam (CLB) was approved in October 2011 by the United States FDA as an adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients older than the age of 2. Due to its unique chemical design and selective binding to the alpha-2 GABA-receptor, CLB has...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-01-01
|
| Series: | Epilepsy & Behavior Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S258998642030054X |